Business / Finance RSS Feed - Business / Finance

Precision for Medicine announces acquisition of Precision Health Economics

Precision for Medicine announces acquisition of Precision Health Economics

Precision for Medicine, a specialized services company supporting next-generation approaches to drug development and commercialization, today announced the acquisition of Precision Health Economics. [More]
ChemRar, Lancet partner to develop and commercialize new medicines in Russia

ChemRar, Lancet partner to develop and commercialize new medicines in Russia

ChemRar High Tech Center, the Russian pharmaceutical investment and R&D group, and Lancet, Russian Distribution Company, have announced collaboration for research, development and commercialization of new medicines in Russia with the intention to stimulate the innovative development of the Russian pharmaceutical industry. [More]

Significant progress for Epigem in SYMPHONY aflatoxin research

Epigem has developed, using microfluidics, a de-fatting device which is as efficient as a centrifuge and will reduce animal tests times from hours to minutes... [More]
India and Canada announce funding to improve maternal, child health in India

India and Canada announce funding to improve maternal, child health in India

Grand Challenges Canada, funded by the Government of Canada, and the Grand Challenges India initiative of the Department of Biotechnology, Government of India, today announced an investment of $2.5 million (CAD) in five health innovations in India. [More]
Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal enters into sales, distribution agreement for BeneFishial family of products

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has entered into a Memorandum of Understanding with Korea Animal Medical Science Institute and its newly created affiliate for the exclusive sales and distribution of the BeneFishial family of products. [More]
SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug. [More]
Optibrium to integrate ChemAxon's Plexus with StarDrop software platform

Optibrium to integrate ChemAxon's Plexus with StarDrop software platform

Optibrium and ChemAxon, developers of software and cheminformatics solutions for drug discovery, today announced the results of a collaboration to integrate ChemAxon's Plexus with Optibrium's StarDrop software suite. The integration of these platforms further enables researchers to develop strategies for efficient, high quality compound library design. [More]
Warfarin and PT-INR testing: an interview with Paul Wright, CEO, Universal Biosensors

Warfarin and PT-INR testing: an interview with Paul Wright, CEO, Universal Biosensors

There are roughly 10 million people worldwide taking Warfarin, accounting for more than 200 million point of care (POC) PT-INR tests performed globally each year... [More]

Clyde Biosciences announces £2 million ‘Series A’ investment

Clyde Biosciences Ltd. has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. [More]
Atlas Genetics signs diagnostic collaboration to explore new use of io system

Atlas Genetics signs diagnostic collaboration to explore new use of io system

Atlas Genetics Ltd, the ultra-rapid 'test and treat' molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases. [More]
iCardiac launches industry-first full risk-sharing program for cardiac safety studies

iCardiac launches industry-first full risk-sharing program for cardiac safety studies

iCardiac Technologies, a market and scientific leader in the conduct of cardiac safety assessments, announced today that it has launched the industry’s first full risk-sharing program for Thorough QT studies. Leveraging its innovative High Precision QT™ methodology for analyzing ECG waveforms, iCardiac’s program guarantees to sponsors that one of two desirable outcomes will be achieved. [More]
BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate™ system to a medical center located in Hungary. [More]

Clyde Biosciences, a leading drug toxicity testing company, closes Series A investment

Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd. [More]
EarlySense signs partnership agreement with Mitsui

EarlySense signs partnership agreement with Mitsui

EarlySense Ltd., the market leader in contact-free monitoring solutions for the hospital and home, announced today it has signed a partnership agreement with Mitsui & Co., Ltd., one of the largest general trading companies in Japan, with revenues of 55.7 Billion USD and net income of 4,099 Million USD for the year ended March 31st, 2014. [More]
Lucideon doubles its wear testing capabilities in the US

Lucideon doubles its wear testing capabilities in the US

Lucideon has invested in a new six station knee wear testing simulator, doubling its capacity to perform knee wear testing for orthopaedic implant manufacturers and taking the total investment in this service to over £1 Million across the group... [More]
LABORIE completes acquisition of Medical Measurement Systems

LABORIE completes acquisition of Medical Measurement Systems

LABORIE Medical Technologies has completed its acquisition of Medical Measurement Systems. MMS is headquartered in Enschede, The Netherlands, with a German subsidiary in Bottrop and US operations in Dover, New Hampshire. [More]
Temple/St. Luke's medical students engage Bangor area sixth graders in active learning about health

Temple/St. Luke's medical students engage Bangor area sixth graders in active learning about health

School to provide an interactive health education and science assembly to interest students in healthy living and disease prevention... [More]
Oxis International resumes trading of common stock on Euronext Paris on April 14, 2015

Oxis International resumes trading of common stock on Euronext Paris on April 14, 2015

Oxis International, Inc., a biotechnology company focused on cancer therapy development and commercialization, announced today that trading in its common stock will resume on Euronext Paris on April 14, 2015. [More]

Special concession on PTI training courses for new and growing life science organisations

Following its recent introduction of innovative game-based e-learning modules, Pharmaceutical Training International (PTI) is providing the opportunity to make substantial savings on its full range of training courses to start-ups and SMEs (with fewer than 50 employees), as well as non-profit organisations and government bodies... [More]
Catamaran acquires Healthcare Solutions for $405 million

Catamaran acquires Healthcare Solutions for $405 million

Catamaran Corporation, a leading provider of pharmacy benefit management (PBM) services and technology solutions, announced today the completion, effective as of April 8, 2015, of its previously disclosed acquisition of Healthcare Solutions, for a purchase price of $405 million in cash, subject to certain customary post-closing adjustments. The purchase price was funded from Catamaran's existing cash balance. [More]
Advertisement
Advertisement